This page shows the latest China biotech news and features for those working in and with pharma, biotech and healthcare.
Vir Biotech has also signed a deal with Biogen for the process development and manufacturing of its antibodies for COVID-19. ... The Biogen agreement builds on Vir Biotech’s additional manufacturing agreements with China-based WuXi Biologics and Incheon
Biotech company Moderna announced yesterday that its has released the first batch of its vaccine – mRNA-1273 – for human use. ... The company has partnered with China-based biotech company Clover Biopharmaceuticals on its protein-based coronavirus
in the China National Reimbursement Drug List (NRDL) at the next update later this year. ... NET) it is on course to file for approval in China before year-end.
The Swedish biotech launched its initial public offering (IPO) on the Stockholm Nasdaq last year, and has now secured a valuable partner which could unlock access to China's huge market. ... China is the world's largest market in terms of the number of
Manufacturing can be cut from two weeks to one day. Gracell Bio has launched its new CAR-T production platform, and the China-based biotech claims its technology can reduce the
The current pace of development of the biotech ecosystem in China is remarkable,” said Simon To, Chi-Med’s chairman. ... It is being fuelled by the major unmet medical needs in China, systemic regulatory reforms that are accelerating new drug
More from news
Approximately 5 fully matching, plus 18 partially matching documents found.
The nation’s biotech boom is rocking the laboratories and trading floors of the world as China secures a place at the forefront of innovative medicine, casting off its reputation as ... At the spear point is China’s emergence as the epicentre of
150. AstraZeneca (UK). 3SBio. Distribution. Byetta, Bydureon (exanatide) for Type 2 diabetes in China. ... 100. Active Biotech (SE). NeoTx (IS). Licence. Tumour Targeting Superantigen ANYARA in phase I for oncology.
The company is expected to launch its products in the US and China. ... Russia's biotech sector has high untapped potential. Rising risks but solid foundations.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Prior to this, he held the same title at RiboBio, an oligonucleotide-focused biotech based in China, between 2011 and 2015, and served as vice president of technology development at RXi
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...